Tianjin TEDA Biomedical Engineering Company Limited
Symbol: 8189.HK
HKSE
0.068
HKDTrhová cena dnes
-5.3122
Pomer P/E
-0.1354
Pomer PEG
148.68M
MRK Cap
- 0.00%
Výnos DIV
Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 78.81 | 5.9 | 9.5 | 29.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 129.84 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.net-receivables | 29.14 | 8.8 | 31.9 | 32.1 | |||||||||||||||||||
balance-sheet.row.inventory | 188.07 | 90.5 | 74 | 75.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 97.68 | 85.2 | 80.3 | 75 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 442.5 | 190.3 | 193.1 | 208.7 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 227.33 | 99.7 | 118.5 | 125 | |||||||||||||||||||
balance-sheet.row.goodwill | 5.53 | 0 | 5.5 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 18.94 | 13.3 | 20.1 | 13.9 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 24.47 | 13.3 | 25.6 | 13.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -203.31 | 0 | -144.1 | -138.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 187.35 | 112.9 | 144.1 | 138.8 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 629.86 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 26.08 | 16.1 | 20.7 | 29.5 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 124.04 | 63.3 | 60.8 | 45.1 | |||||||||||||||||||
balance-sheet.row.tax-payables | 2.34 | 0 | 3.1 | 1.5 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.53 | 20.3 | 35.2 | 45.2 | |||||||||||||||||||
Deferred Revenue Non Current | -1.56 | -1.6 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.56 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 164.22 | 13.4 | 136.7 | 117.4 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 57.09 | 21.9 | 35.2 | 45.2 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 51.09 | 11.9 | 39.2 | 42.9 | |||||||||||||||||||
balance-sheet.row.total-liab | 495.52 | 238.7 | 253.5 | 237.2 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 131.74 | 3.7 | 16.8 | 16.8 | |||||||||||||||||||
balance-sheet.row.common-stock | 378.9 | 189.4 | 189.4 | 189.4 | |||||||||||||||||||
balance-sheet.row.retained-earnings | -791.91 | -401.7 | -379 | -350.9 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -10.77 | -16.8 | -16.8 | -16.8 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 556.88 | 275.3 | 262.2 | 262.2 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 264.85 | 50 | 72.7 | 100.8 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.33 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 22.96 | 14.6 | 11 | 9.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 287.81 | 64.6 | 83.7 | 110.4 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.33 | - | - | - | |||||||||||||||||||
Total Investments | 129.84 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.total-debt | 179.57 | 83.6 | 96 | 90.3 | |||||||||||||||||||
balance-sheet.row.net-debt | 230.6 | 77.6 | 89.2 | 63.9 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.16 | -26.5 | -44.8 | -50 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 15.4 | 9.5 | 7.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1.7 | -5.3 | 43.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | -2.1 | 0.1 | -4.3 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 1.2 | 16.4 | -2.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.1 | -0.1 | 4.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -3 | -21.8 | 46.2 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 20.16 | 0 | 34 | 35.4 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2.17 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.46 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6.4 | 1.1 | 1.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -22.8 | -22 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0.7 | 43.8 | -1.9 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1.5 | 3 | 10.3 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -1.46 | -12.9 | -8.5 | -26.5 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -46.8 | -16 | -31.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 53 | 44.1 | 11 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6.2 | 28.1 | -20.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0.38 | -19.6 | 12.9 | -10.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 8.07 | 6.9 | 26.4 | 13.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7.7 | 26.4 | 13.5 | 24.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 2.17 | -12.8 | -6.7 | 36 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -1.46 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0.71 | -21.6 | -40.4 | 22 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 398 | 398 | 449.7 | 476.4 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 376.63 | 376.6 | 433.3 | 430.8 | |||||||||||||||||||
income-statement-row.row.gross-profit | 21.37 | 21.4 | 16.4 | 45.6 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 1.32 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 9.74 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 8.1 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -0.32 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 31.2 | 31.2 | 38.5 | 51.8 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 407.83 | 407.8 | 471.8 | 482.5 | |||||||||||||||||||
income-statement-row.row.interest-income | 4.92 | 0.2 | 0.8 | 0.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 5.17 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 8.1 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.96 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -0.32 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 5.96 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 5.17 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.37 | 11.6 | 15.4 | 9.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | -9.9 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | -17.97 | -19.3 | -20.8 | -4.4 | |||||||||||||||||||
income-statement-row.row.income-before-tax | -12.01 | -12 | -26.5 | -44.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | -0.86 | -1 | 0.2 | -0.1 | |||||||||||||||||||
income-statement-row.row.net-income | -21.99 | -20.2 | -26.6 | -44.8 |
Často kladené otázky
Čo je Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) celkové aktíva?
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) celkové aktíva sú 303277966.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 212082169.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.054.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 0.000.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.055.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.045.
Aká je Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -20159658.000.
Aký je celkový dlh firmy?
Celkový dlh je 83557328.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 31200528.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 5934322.000.